RTC XXX
Alternative Names: RTC-XXXLatest Information Update: 14 Jan 2022
At a glance
- Originator Ripple Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Dry age-related macular degeneration
Highest Development Phases
- Research Dry age-related macular degeneration
Most Recent Events
- 03 Jan 2022 RTC XXX is available for licensing as of 03 Jan 2022. https://www.rippletherapeutics.com/
- 03 Jan 2022 Early research in Dry age-related macular degeneration in Canada (Intravitreous) before January 2022 (Ripple Therapeutics, January 2022)